An Exploratory Phase 2a, Randomised, Double-blind, Placebo-controlled Study to Evaluate the Effect of MEDI0382 on Energy Balance in Overweight and Obese Subjects With Type 2 Diabetes Mellitus
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 17 Sep 2019
Price : $35 *
At a glance
- Drugs Cotadutide (Primary)
- Indications Obesity
- Focus Therapeutic Use
- Sponsors MedImmune
- 13 Sep 2019 Planned End Date changed from 9 Dec 2019 to 27 Dec 2019.
- 13 Sep 2019 Planned primary completion date changed from 9 Dec 2019 to 27 Dec 2019.
- 13 Sep 2019 Status changed from recruiting to active, no longer recruiting.